ParcelBio
ParcelBio

ParcelBio

DR17Ahrefs DR: 17/100. Bottom 25%. Measured by Ahrefs. Median 44.Agent33Agent Readiness: 33/100. Below median. Measured by StartupHub.ai. Median 41.Speed60Site Speed: 60/100. Below median. Measured by Google PageSpeed. Median 62.

Advancing next-generation mRNA medicines.

Website
2023Active6San Francisco, USA

About

ParcelBio is developing transformative mRNA medicines using its proprietary APEXm™ platform, engineered for significantly higher potency and durability than existing mRNA technologies. This platform enables a new class of therapies, including in vivo CAR-T for autoimmune diseases and oncology, and durable delivery of therapeutic proteins. ParcelBio serves patients by creating advanced mRNA medicines that can reach therapeutic thresholds previously unattainable.

Key facts

At-a-glance profile data

Website
parcelbio.com
Headquarters
San Francisco, California, USA
Founded
2023
Employees
6
Total funding
$100M (Series A)
Business model
B2B

Funding rounds

Funding rounds raised by ParcelBio
DateRoundAmountLead investors
18 Jan 2023Series A$100M-

Tech stack

Detected on parcelbio.com, last scanned 19 Sept 2026. Run your own scan

CMS / Builders
Webflow
CDN
Cloudflare
Email provider
Microsoft 365
Add first review

Frequently asked

How much funding has ParcelBio raised?

ParcelBio has raised a total of $100M in funding. The most recent round on record is Series A.

How many employees does ParcelBio have?

ParcelBio has approximately 6 people on record.